INTERVENTION 1:	Intervention	0
Exemestane	Intervention	1
exemestane	CHEBI:4953	0-10
Patients receive oral exemestane (25 mg) once daily for 5 years.	Intervention	2
exemestane	CHEBI:4953	22-32
exemestane: Given orally	Intervention	3
exemestane	CHEBI:4953	0-10
INTERVENTION 2:	Intervention	4
Anastrozole	Intervention	5
anastrozole	CHEBI:2704	0-11
Patients receive oral anastrozole (1 mg) once daily for 5 years.	Intervention	6
anastrozole	CHEBI:2704	22-33
anastrozole: Given orally	Intervention	7
anastrozole	CHEBI:2704	0-11
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically confirmed invasive breast cancer	Eligibility	1
breast cancer	DOID:1612	34-47
pT1-3; pNX, pN0-2 or pN3*; M0	Eligibility	2
Neoadjuvant patients are eligible no earlier than 3 weeks or later than 3 months after excisional surgery, provided both the clinical-diagnostic staging of cancer and postsurgical resection-pathologic staging of cancer meet the requirements for primary tumor, regional lymph nodes, and distant metastasis classification NOTE: *Only when the sole basis for this classification is the presence of 10 or more involved axillary lymph nodes	Eligibility	3
surgery	OAE:0000067	98-105
cancer	DOID:162	156-162
cancer	DOID:162	212-218
lymph	UBERON:0002391	269-274
lymph	UBERON:0002391	424-429
Completely resected disease	Eligibility	4
disease	DOID:4,OGMS:0000031	20-27
Primary surgery performed at least 3 weeks but no more than 3 months before study entry (if no chemotherapy was given)	Eligibility	5
surgery	OAE:0000067	8-15
Primary surgery is defined as the last surgery at which histologic evidence of invasive or in situ disease was present in the pathology specimen	Eligibility	6
surgery	OAE:0000067	8-15
surgery	OAE:0000067	39-46
disease	DOID:4,OGMS:0000031	99-106
present	PATO:0000467	111-118
Patients with positive sentinel lymph node biopsy are eligible provided they have had a subsequent axillary lymph node dissection	Eligibility	7
lymph	UBERON:0002391	32-37
lymph	UBERON:0002391	108-113
No metachronous breast cancer	Eligibility	8
breast cancer	DOID:1612	16-29
Bilateral mammogram within the past 12 months unless initial surgery was a total mastectomy, in which case only a mammogram of the remaining breast is required	Eligibility	9
bilateral	HP:0012832	0-9
surgery	OAE:0000067	61-68
breast	UBERON:0000310	141-147
No metastases confirmed by 1 of the following methods:	Eligibility	10
Bone scan* (required only if alkaline phosphatase is at least 2 times normal and/or there are symptoms of metastatic disease)	Eligibility	11
phosphatase	GO:0016791,BAO:0000295	38-49
disease	DOID:4,OGMS:0000031	117-124
Abdominal ultrasound or CT scan (required only if AST/ALT or alkaline phosphatase is at least 2 times normal, unless the elevation is in the bone fraction)	Eligibility	12
ct	BAO:0002125	24-26
ct	BAO:0002125	149-151
phosphatase	GO:0016791,BAO:0000295	70-81
Chest x-ray NOTE: *Confirmatory x-ray, CT scan, or MRI required if the bone scan results are questionable	Eligibility	13
chest	UBERON:0001443	0-5
ct	BAO:0002125	39-41
No locally recurrent disease	Eligibility	14
recurrent	HP:0031796	11-20
disease	DOID:4,OGMS:0000031	21-28
No prior or concurrent carcinoma in situ of the contralateral breast treated with partial mastectomy and/or hormonal therapy	Eligibility	15
carcinoma	HP:0030731,DOID:305	23-32
breast	UBERON:0000310	62-68
Patients with prior or concurrent carcinoma in situ of the ipsilateral breast are eligible provided the tumor was completely excised AND they have not received prior hormonal therapy	Eligibility	16
carcinoma	HP:0030731,DOID:305	34-43
breast	UBERON:0000310	71-77
Hormone receptor status:	Eligibility	17
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Estrogen receptor- and/or progesterone receptor-positive by immunohistochemistry or tumor receptor content  10 fmol/mg protein	Eligibility	18
estrogen	CHEBI:50114,BAO:0000760	0-8
progesterone	CHEBI:17026	26-38
immunohistochemistry	BAO:0000415	60-80
receptor	BAO:0000281	9-17
receptor	BAO:0000281	39-47
receptor	BAO:0000281	90-98
protein	CHEBI:36080,BAO:0000175	119-126
PATIENT CHARACTERISTICS:	Eligibility	19
patient	HADO:0000008,OAE:0001817	0-7
Age	Eligibility	20
age	PATO:0000011	0-3
Postmenopausal	Eligibility	21
Sex	Eligibility	22
Female	Eligibility	23
female	PATO:0000383	0-6
Menopausal status	Eligibility	24
Postmenopausal prior to chemotherapy, defined as 1 of the following:	Eligibility	25
Over 60 years of age	Eligibility	26
age	PATO:0000011	17-20
Age 45-59 with spontaneous cessation of menses for more than 1 year prior to study entry	Eligibility	27
age	PATO:0000011	0-3
year	UO:0000036	63-67
Age 45-59 with menses ceasing (secondary to hysterectomy or spontaneously) within the past year AND a follicle-stimulating hormone (FSH) level prior to study entry in the postmenopausal range*	Eligibility	28
age	PATO:0000011	0-3
year	UO:0000036	91-95
hormone	CHEBI:24621	123-130
range	LABO:0000114	186-191
Age 45-59, previously on hormone replacement therapy (HRT) and have discontinued HRT upon diagnosis of this malignancy AND has an FSH level prior to study entry in the postmenopausal range*	Eligibility	29
age	PATO:0000011	0-3
hormone	CHEBI:24621	25-32
range	LABO:0000114	183-188
Has undergone bilateral oophorectomy NOTE: *By institutional standards OR > 34.4 IU/L if institutional range is not available)	Eligibility	30
bilateral	HP:0012832	14-23
range	LABO:0000114	103-108
Performance status	Eligibility	31
ECOG 0-2	Eligibility	32
Life expectancy	Eligibility	33
At least 5 years	Eligibility	34
Hematopoietic	Eligibility	35
WBC at least 3,000/mm^3 OR	Eligibility	36
Granulocyte count at least 1,500/mm^3 AND	Eligibility	37
Platelet count at least 100,000/mm^3	Eligibility	38
platelet count	CMO:0000029	0-14
Hepatic	Eligibility	39
See Disease Characteristics	Eligibility	40
disease	DOID:4,OGMS:0000031	4-11
AST and/or ALT less than 2 times upper limit of normal (ULN)*	Eligibility	41
Alkaline phosphatase less than 2 times ULN* NOTE: *Unless imaging examinations have ruled out metastatic disease	Eligibility	42
phosphatase	GO:0016791,BAO:0000295	9-20
disease	DOID:4,OGMS:0000031	105-112
Renal	Eligibility	43
Not specified	Eligibility	44
Other	Eligibility	45
Able to swallow study medication and have adequate unassisted oral intake in order to maintain reasonable nutrition status	Eligibility	46
No other non-breast malignancy within the past 5 years except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumors with no evidence of disease for at least 5 years	Eligibility	47
skin cancer	DOID:4159	93-104
carcinoma	HP:0030731,DOID:305	125-134
disease	DOID:4,OGMS:0000031	219-226
No other concurrent medical or psychiatric condition that would preclude study participation and/or interfere with results	Eligibility	48
condition	PDRO:0000129	43-52
PRIOR CONCURRENT THERAPY:	Eligibility	49
Biologic therapy	Eligibility	50
Prior and concurrent trastuzumab (HerceptinÂ®) allowed	Eligibility	51
Chemotherapy	Eligibility	52
See Disease Characteristics	Eligibility	53
disease	DOID:4,OGMS:0000031	4-11
At least 3 weeks but no more than 3 months since prior chemotherapy	Eligibility	54
Prior adjuvant chemotherapy allowed	Eligibility	55
adjuvant	CHEBI:60809	6-14
Endocrine therapy	Eligibility	56
See Disease Characteristics	Eligibility	57
disease	DOID:4,OGMS:0000031	4-11
No prior aromatase inhibitor	Eligibility	58
inhibitor	CHEBI:35222	19-28
No prior tamoxifen or other selective estrogen receptor modulators (SERMs) except raloxifene	Eligibility	59
tamoxifen	CHEBI:41774	9-18
estrogen	CHEBI:50114,BAO:0000760	38-46
receptor	BAO:0000281	47-55
raloxifene	CHEBI:8772	82-92
At least 3 weeks since prior raloxifene	Eligibility	60
raloxifene	CHEBI:8772	29-39
At least 3 weeks since prior and no concurrent over-the-counter products or supplements considered to have an estrogenic effect, including any of the following:	Eligibility	61
Ginseng	Eligibility	62
Ginkgo biloba	Eligibility	63
Black cohosh	Eligibility	64
Dong quai	Eligibility	65
Fortified soy supplements (e.g., phytoestrogen preparations)	Eligibility	66
phytoestrogen	CHEBI:76989	33-46
At least 3 weeks since other prior hormonal therapy or steroids considered to have an estrogenic effect	Eligibility	67
No concurrent estrogens, progesterones, androgens, or SERMs	Eligibility	68
Concurrent intermittent vaginal estrogens (e.g., vagifem, estrogen vaginal cream, testosterone, estradiol vaginal gel, or Estring) allowed if other local measures for intractable vaginal atrophy are insufficient	Eligibility	69
estrogen	CHEBI:50114,BAO:0000760	32-40
estrogen	CHEBI:50114,BAO:0000760	58-66
testosterone	CHEBI:17347	82-94
estradiol	CHEBI:23965	96-105
gel	BAO:0010018	114-117
No other concurrent therapy that would have an estrogenic effect, including endocrine therapy, hormonal therapy, or steroid therapy	Eligibility	70
steroid	CHEBI:35341	116-123
Radiotherapy	Eligibility	71
radiotherapy	OAE:0000235	0-12
See Disease Characteristics	Eligibility	72
disease	DOID:4,OGMS:0000031	4-11
Prior adjuvant radiotherapy allowed	Eligibility	73
adjuvant	CHEBI:60809	6-14
radiotherapy	OAE:0000235	15-27
Concurrent radiotherapy allowed	Eligibility	74
radiotherapy	OAE:0000235	11-23
Surgery	Eligibility	75
surgery	OAE:0000067	0-7
See Disease Characteristics	Eligibility	76
disease	DOID:4,OGMS:0000031	4-11
Outcome Measurement:	Results	0
Event-free Survival	Results	1
Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause.	Results	2
time	PATO:0000165	75-79
time	PATO:0000165	106-110
breast cancer	DOID:1612	173-186
death	OAE:0000632	191-196
Time frame: 5 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Exemestane	Results	5
exemestane	CHEBI:4953	17-27
Arm/Group Description: Patients receive oral exemestane (25 mg) once daily for 5 years.	Results	6
exemestane	CHEBI:4953	45-55
exemestane: Given orally	Results	7
exemestane	CHEBI:4953	0-10
Overall Number of Participants Analyzed: 3789	Results	8
Measure Type: Number	Results	9
Unit of Measure: percentage of participants  88        (87 to 89)	Results	10
Results 2:	Results	11
Arm/Group Title: Anastrozole	Results	12
anastrozole	CHEBI:2704	17-28
Arm/Group Description: Patients receive oral anastrozole (1 mg) once daily for 5 years.	Results	13
anastrozole	CHEBI:2704	45-56
anastrozole: Given orally	Results	14
anastrozole	CHEBI:2704	0-11
Overall Number of Participants Analyzed: 3787	Results	15
Measure Type: Number	Results	16
Unit of Measure: percentage of participants  89        (88 to 90)	Results	17
Adverse Events 1:	Adverse Events	0
Total: 19/3761 (0.51%)	Adverse Events	1
Cardiac ischemia/infarction 3/3761 (0.08%)	Adverse Events	2
Left ventricular systolic dysfunction 1/3761 (0.03%)	Adverse Events	3
left ventricular systolic dysfunction	HP:0025169	0-37
Restrictive cardiomyopathy 1/3761 (0.03%)	Adverse Events	4
restrictive cardiomyopathy	HP:0001723,DOID:397	0-26
Supraven.arrhyth. Atrial flutter 1/3761 (0.03%)	Adverse Events	5
atrial flutter	HP:0004749	18-32
Ventric.arrhyth. Trigeminy 1/3761 (0.03%)	Adverse Events	6
Hypothyroidism 0/3761 (0.00%)	Adverse Events	7
hypothyroidism	HP:0000821,DOID:1459	0-14
Blurred vision 1/3761 (0.03%)	Adverse Events	8
blurred vision	HP:0000622	0-14
Nyctalopia 0/3761 (0.00%)	Adverse Events	9
nyctalopia	HP:0000662,DOID:8499	0-10
Ocular - Other 1/3761 (0.03%)	Adverse Events	10
Adverse Events 2:	Adverse Events	11
Total: 7/3759 (0.19%)	Adverse Events	12
Cardiac ischemia/infarction 0/3759 (0.00%)	Adverse Events	13
Left ventricular systolic dysfunction 0/3759 (0.00%)	Adverse Events	14
left ventricular systolic dysfunction	HP:0025169	0-37
Restrictive cardiomyopathy 0/3759 (0.00%)	Adverse Events	15
restrictive cardiomyopathy	HP:0001723,DOID:397	0-26
Supraven.arrhyth. Atrial flutter 0/3759 (0.00%)	Adverse Events	16
atrial flutter	HP:0004749	18-32
Ventric.arrhyth. Trigeminy 0/3759 (0.00%)	Adverse Events	17
Hypothyroidism 1/3759 (0.03%)	Adverse Events	18
hypothyroidism	HP:0000821,DOID:1459	0-14
Blurred vision 0/3759 (0.00%)	Adverse Events	19
blurred vision	HP:0000622	0-14
Nyctalopia 1/3759 (0.03%)	Adverse Events	20
nyctalopia	HP:0000662,DOID:8499	0-10
Ocular - Other 0/3759 (0.00%)	Adverse Events	21
